Kodiak Sciences Surges 64% as Eye Drugs Hit Trial Goals, BLA Filing Set for Q4
KOD has more than doubled off its 52-week low of $10.94 on elevated volume (3.2× avg).
Summary
Kodiak Sciences shares jumped 64% to $54.42 in premarket trading after both Zenkuda and KSI-501 met primary endpoints in the pivotal DAYBREAK trial for wet AMD. The company plans to file a BLA for Zenkuda in Q4, potentially bringing its first commercial product to market. This follows the earlier Reuters report of the trial success, but adds the dramatic market reaction and the specific regulatory filing timeline. The stock is now trading near its 52-week high, reflecting strong investor enthusiasm for the company's first potential approval.
At the time of this announcement, KOD was trading at $51.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.94 to $47.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.